TABLE 2.
First‐line to fourth‐line cabozantinib treatment outcomes
| First line | Second line | Third line | Fourth line | Post first‐line IO Combos | ||
|---|---|---|---|---|---|---|
| ORR | 32% (9/28) | 26% (28/109) | 25% (25/102) | 29% (19/65) | 22% (5/23) | |
| Best response | ||||||
| CR | 0% (0/28) | 1% (1/109) | 0% (0/102) | 2% (1/65) | 0% (0/23) | |
| PR | 32% (9/28) | 25% (27/109) | 25% (25/102) | 28% (18/65) | 22% (5/23) | |
| SD | 50% (14/28) | 52% (57/109) | 48% (49/102) | 49% (32/65) | 57% (13/23) | |
| PD | 18% (5/28) | 22% (24/109) | 28% (28/102) | 22% (14/65) | 21% (5/23) | |
| TTF (mo) (95% CI) | 8.3 (4.6–16.0) | 7.3 (5.5–8.2) | 7.0 (5.0–9.4) | 8.0 (5.6–10.4) | 5.4 (4.4–5.8) | |
| Median OS (mo) (95% CI) | 30.7 (15.8–36.8) | 17.8 (11.9–23.3) | 12.6 (9.3–21.7) | 14.9 (10.2–21.7) | 17.4 (4.8–23.3) | |
IO Combos include Ipilimumab/Nivolumab (n = 5) and various PD(L)1 + VEGF inhibitor combinations (n = 18).
Abbreviations: CI, confidence interval; CR, complete response; PD, progressive disease; PR, partial response; SD, stable disease.